Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

This phase 2 study evaluated isatuximab as monotherapy or combined with dexamethasone in relapsed/refractory multiple myeloma (RRMM). Patients had RRMM refractory to an immunomodulatory drug (IMiD) and a proteasome inhibitor (PI) or had received ≥3 prior lines of therapy incorporating an IMiD and PI...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Blood
Main Authors: Dimopoulos, Meletios, Bringhen, Sara, Anttila, Pekka, Capra, Marcelo, Cavo, Michele, Cole, Craig, Gasparetto, Cristina, Hungria, Vania, Jenner, Matthew, Vorobyev, Vladimir, Ruiz, Eduardo Yanez, Yin, Jian Y., Saleem, Rao, Hellet, Maeva, Macé, Sandrine, Paiva, Bruno, Vij, Ravi
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Hematology 2021
נושאים:
Clinical Trials and Observations
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7933767/
https://ncbi.nlm.nih.gov/pubmed/33080623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020008209
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים